Monte Rosa Therapeutics, Inc. (GLUE) News
Track canonical SquawkNews coverage tagged to GLUE, Monte Rosa Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
EQUITY | Jul 27, 2026, 01:20 PM UTC
L
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35.
EQUITY | Jun 30, 2026, 01:54 PM UTC